Clinical Trials Arena on MSN7h
Boehringer seeks approval of lung disease drug after second Phase III successBoehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Comedy fans can catch Johnny Pizzi, Mark Riley, and Artie Januario at Giggles Comedy Club on Feb. 13 for a fundraiser ...
Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...
Zacks Investment Research on MSN3d
Insmed's NDA for Lung Disease Drug Gets FDA's Priority ReviewInsmed Incorporated INSM announced that the FDA has accepted its new drug application (“NDA”) seeking approval of its reversible inhibitor of dipeptidyl peptidase 1 (DPP1), brensocatib, for treating ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
WILMORE, Ky. (WKYT) - A Wilmore woman made quite the discovery after receiving results from a DNA kit, one that would lead to ...
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback